Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Collecting Duct Carcinoma Clear all
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radium Ra 223 Dichloride
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Kidney Cancer
Interventions
Everolimus, Sunitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced May 21, 2026, 6:54 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Renal Cell Carcinoma, Unresectable Advanced Renal Cell Carcinoma, Metastatic Ncc Renal Cell Carcinoma
Interventions
Cabozantinib, Nivolumab, Ipilimumab
Drug
Lead sponsor
Bradley A. McGregor, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
epothilone b
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Kidney Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
35
States / cities
Jacksonville, Florida • Aurora, Illinois • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced May 21, 2026, 6:54 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
Interventions
cabozantinib, nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Kidney Oncocytoma, Metastatic Renal Cell Cancer, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Pazopanib Hydrochloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
578
States / cities
Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Renal Cell Cancer, Kidney Cancer
Interventions
Sunitinib Malate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced May 21, 2026, 6:54 PM EDT